Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of (2R)-(3-amino-2-fluoropropyl)sulphinic acid (AFPSiA) on transient lower oesophageal sphincter relaxation in dogs and mechanism of hypothermic effects in mice.
Lehmann A, Holmberg AA, Bhatt U, Bremner-Danielsen M, Brändén L, Elg S, Elebring T, Fitzpatrick K, Geiss WB, Guzzo P, Jensen J, Jerndal G, Mattsson JP, Nilsson K, Olsson BM. Lehmann A, et al. Br J Pharmacol. 2005 Sep;146(1):89-97. doi: 10.1038/sj.bjp.0706299. Br J Pharmacol. 2005. PMID: 15980875 Free PMC article.
(R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action.
Lehmann A, Antonsson M, Holmberg AA, Blackshaw LA, Brändén L, Bräuner-Osborne H, Christiansen B, Dent J, Elebring T, Jacobson BM, Jensen J, Mattsson JP, Nilsson K, Oja SS, Page AJ, Saransaari P, von Unge S. Lehmann A, et al. J Pharmacol Exp Ther. 2009 Nov;331(2):504-12. doi: 10.1124/jpet.109.153593. Epub 2009 Jul 31. J Pharmacol Exp Ther. 2009. PMID: 19648470
Different in vitro and in vivo profiles of substituted 3-aminopropylphosphinate and 3-aminopropyl(methyl)phosphinate GABA(B) receptor agonists as inhibitors of transient lower oesophageal sphincter relaxation.
Lehmann A, Antonsson M, Aurell-Holmberg A, Blackshaw LA, Brändén L, Elebring T, Jensen J, Kärrberg L, Mattsson JP, Nilsson K, Oja SS, Saransaari P, von Unge S. Lehmann A, et al. Br J Pharmacol. 2012 Mar;165(6):1757-1772. doi: 10.1111/j.1476-5381.2011.01682.x. Br J Pharmacol. 2012. PMID: 21950457 Free PMC article.
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
Alstermark C, Amin K, Dinn SR, Elebring T, Fjellström O, Fitzpatrick K, Geiss WB, Gottfries J, Guzzo PR, Harding JP, Holmén A, Kothare M, Lehmann A, Mattsson JP, Nilsson K, Sundén G, Swanson M, von Unge S, Woo AM, Wyle MJ, Zheng X. Alstermark C, et al. Among authors: lehmann a. J Med Chem. 2008 Jul 24;51(14):4315-20. doi: 10.1021/jm701425k. Epub 2008 Jun 25. J Med Chem. 2008. PMID: 18578471
Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.
Plowright AT, Nilsson K, Antonsson M, Amin K, Broddefalk J, Jensen J, Lehmann A, Jin S, St-Onge S, Tomaszewski MJ, Tremblay M, Walpole C, Wei Z, Yang H, Ulander J. Plowright AT, et al. Among authors: lehmann a. J Med Chem. 2013 Jan 10;56(1):220-40. doi: 10.1021/jm301511h. Epub 2012 Dec 24. J Med Chem. 2013. PMID: 23227781
1,172 results